Cytotoxicity Assays

Cytotoxicity testing is an irreplaceable cornerstone of preclinical safety evaluation in full-process lead compound drug development, serving as a mandatory forward safety checkpoint before candidate lead compounds enter subsequent in vivo efficacy verification and formal pharmacodynamic research. As a core standardized testing item that fully complies with GLP laboratory specifications and international pharmaceutical preclinical research guidelines, systematic cytotoxicity profiling accurately evaluates the inhibitory effect of synthesized and optimized lead compounds on normal proliferating cells, abnormal damage to functional metabolic cells, and irreversible apoptosis damage induced by compound concentration gradients. High-quality, reproducible cytotoxicity original data can effectively avoid major R&D losses caused by excessive toxic side effects of lead compounds in the late preclinical stage, provide objective and reliable safety basis for researchers to screen, optimize and eliminate invalid toxic lead molecules in the early research stage, and standardly support batch sorting, IC50 toxicity grading and structural optimization iteration of lead compound libraries, which is a key technical guarantee to improve the overall success rate of pharmaceutical lead compound development and shorten the overall R&D cycle of new drugs.

PharmaAnalytica, an independent high-end analytical testing brand under STEMart, provides full-parameter customized cytotoxicity assay services exclusively for pharmaceutical lead compound optimization and preclinical safety screening, with a complete series of fully validated mainstream detection technical routes covering all scenario demands of lead compound batch screening, single-to-medium dose toxicity verification and mechanism preliminary exploration. The portfolio includes:

• Colorimetric Assays (MTT, CCK-8): A high-throughput cytotoxicity screening tool quantifies viable cell populations by detecting intracellular mitochondrial metabolic activity.
• LDH Release Assay: Evaluates early plasma membrane integrity damage triggered by lead compound exposure by measuring extracellular lactate dehydrogenase leakage.
• Neutral Red Uptake Assay: Assesses lysosomal structural and functional damage induced by lead compounds, featuring strong anti-interference performance and broad compatibility with both lipophilic and hydrophilic drug solvents.
• Fluorescence-based Methods (AO/PI, Hoechst 33342 staining): Enables clear morphological visualization of early apoptosis, late apoptosis, and necrosis induced by lead compounds under microscopic observation.
• Colony Formation Assays: Detects inhibitory effects of trace toxic chemical moieties on cell clonogenic proliferation capacity.

PharmaAnalytica's Technology Platform

PharmaAnalytica's Cytotoxicity Assay Service

Expert Team & Regulatory Compliance

Our scientists hold extensive experience in GLP-compliant cytotoxicity testing, ensuring all protocols align with ISO 10993-5, OECD, and pharmacopoeia standards.

Customized Assay Design

We tailor testing panels, cell lines (e.g., HeLa, HepG2, L929), and endpoints to your specific research goals, from early-stage compound screening to post-market safety verification.

Comprehensive Data Analysis & Reporting

We deliver detailed, interpretable reports including raw data, IC50/EC50 values, statistical analysis, and morphological images, supporting manuscript preparation and regulatory submissions.

Fast Turnaround & Cost-Effectiveness

Leveraging high-performance instruments and optimized workflows, we provide reliable results with shorter lead times and competitive pricing, accelerating your research timeline.

PharmaAnalytica's high-quality cytotoxicity assay services focus on the whole lifecycle safety escort of pharmaceutical lead compound development, with reliable domestic instrument guarantee, professional technical support and efficient compliant output, helping global pharmaceutical research institutions efficiently screen high-quality low-toxicity lead compounds and accelerate the overall progress of new drug preclinical R&D projects.